Prosecution Insights
Last updated: November 13, 2026
Application No. 18/489,854

DOSING REGIMEN FOR GP100-SPECIFIC TCR - ANTI-CD3 SCFV FUSION PROTEIN

Non-Final OA §DP
Filed
Oct 19, 2023
Priority
Jun 02, 2016 — GB 1609683.6 +4 more
Examiner
SKELDING, ZACHARY S
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Immunocore Limited
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
500 granted / 836 resolved
At TC average
Strong +41% interview lift
Without
With
+41.3%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
48 currently pending
Career history
881
Total Applications
across all art units

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1, 3, 4, 10-13 and 17-20 are pending and under examination. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 3, 4, 10-13 and 17-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-14 of U.S. Patent No. 11827688 in view of Oates et al. (Mol Immunol. 2015 Oct;67(2 Pt A):67-74), Sharma et al. (Cell. 2015 Apr 9;161(2):205-14) and Gros et al. (J Clin Invest. 2014;124(5):2246-2259) (all cited herewith). Reference claim 8 is drawn to: “A method of treating gp100 positive cancer in a patient, comprising: administering to said patient a plurality of doses of a T cell redirecting bispecific therapeutic which comprises (1) a targeting moiety that binds the YLEPGPVTA (SEQ ID NO:1)-HLA-A2 complex fused to (2) a CD3 binding T cell redirection moiety, wherein the bispecific therapeutic includes (a) a TCR alpha chain amino acid sequence selected from the group consisting of…(v) the TCR alpha chain sequence of SEQ ID No: 2, wherein amino acids 1 to 109 are replaced by the sequence of SEQ ID No: 4, wherein amino acid at position 1 is A, and the C-terminus of the alpha chain is truncated by 8 amino acids from F196 to S203 inclusive, based on the numbering of SEQ ID No: 2;…(viii) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acids at positions 1 and 2 are A and I respectively; …wherein the method comprises administration of: (a) at least one first dose in the range of from 10-30 fig; (b) at least one second dose in the range of from 20-40 μg, wherein the second dose is higher than the first dose; and then (c) at least one dose of at least 50 μg, wherein the bispecific therapeutic is administered in combination with one or more anti-cancer therapies.” However, the reference claims do not teach the treatment of advanced melanoma using the redirecting bispecific therapeutic in combination with a PD-1 checkpoint inhibitor such as pembrolizumab. As a preliminary matter, note that according to the instant specification / the reference patent, “IMCgp100” is a T cell redirecting bispecific agent comprising a soluble affinity enhanced TCR that binds to the YLEPGPVTA peptide -HLA-A*02 complex fused to an anti-CD3, wherein “the alpha and beta chains of IMCgp100 are SEQ ID NOs: 4 and 5” (see page 20, last full paragraph of the instant specification). Parts (v) and (viii) of reference claim 1 recite TCR alpha and beta chain sequences that are identical to SEQ ID NOs: 4 and 5 of the IMCgp100 T cell redirecting bispecific therapeutic. With respect to using a redirecting bispecific therapeutic, such as the T cell redirecting bispecific agent IMCgp100, for the treatment of advanced melanoma in combination with a checkpoint inhibitor, the conclusion of Oates states the following: 6. Concluding remarks—perspectives "ImmTACs form a new platform of bispecific reagents for targeted cancer therapy with the potential to overcome T cell tolerance and mediate a durable immune response in vivo. A first ImmTAC (IMCgp100) has completed Phase I clinical testing in patients with advanced melanoma and is currently being evaluated in a Phase IIa study. The drug appears to be well-tolerated with highly encouraging signs of efficacy in a number of patients (Middleton et al., 2014). While ImmTACs are likely to be powerful reagents in a monotherapy setting, it is unlikely that they, or indeed any single agent, will be able to drive complete tumour eradication in most patients. Tumour biology is in all probability too complex and diverse for one agent to emerge as a panacea. This has been evidenced by genome sequencing demonstrating the heterogeneous nature of cancers, even within the same patient, as well as the diverse array of mutations that may be present in such cells (Watson et al., 2013). Furthermore, clonal evolution of cancer cells via Darwinian style selection (reviewed in Greaves and Maley, 2012) means that tumours can also adapt to environmental pressures. A consequence of which is that therapeutic interventions may instigate the emergence, or enrichment, of a resistant population, for example through antigen loss. To circumvent such issues, successful cancer immunotherapy will most likely require the combination of different reagents to induce a multifaceted attack on the tumour to overcome tolerance. The challenge moving forward is to define which combinations will be the most efficacious, and this will demand a greater understanding of the complex interactions between tumours and the immune system. Recent investigations with checkpoint inhibitors have indicated the additive effects of combining two such reagents (Wolchok et al., 2013) (although it is also worth noting that incidence of immune-related toxicities also increased in this study). ImmTACs provide a first-in-class tool to add to the armoury of possible therapeutic combinations, acting through a novel mechanism that may complement and proficiently synergise with other treatment modalities. It will be particularly interesting to combine a targeted therapy such as an ImmTAC with a more systemic treatment such as a checkpoint inhibitor. One could envisage how such a scenario should give rise to a strong and specific anti-tumour response complemented by a broad systemic activation of the immune system, thereby providing necessary impetus to overcome tolerance whilst maintaining a high level of tumour specificity.” (see Section 6, emphasis added). Oates further described how the work of Bossi et al., 2014 (cited below) demonstrated the ability of an ImmTAC specific for a HLA-A*02-restricted peptide from the melanoma antigen gp100 can promote tumor cell killing, which, in turn, release tumor associated antigens thereby triggering anti-tumor “epitope spreading”: “A recent study has provided indications that ImmTAC-redirected tumour killing may induce further amplification of the anti-tumour immune response via antigen cross-presentation and epitope spreading (Bossi et al., 2014) (Fig. 2D). In this work an ImmTAC specific for a HLA-A*02-restricted peptide from the melanoma antigen gp100 was used in conjunction with in vitro assays to demonstrate that ImmTAC-redirected melanoma cell killing leads to antigen uptake by dendritic cells (DCs) and subsequent cross-presentation of gp100. In vivo, mature DCs that have acquired antigen at the tumour site are thought to migrate to the draining lymph nodes where they present the antigen to naïve T cells (Berard et al., 2000). These T cells may then undergo clonal expansion and migrate to the tumour site using a homing mechanism where they can mediate further destruction of tumour cells. The presence of tertiary lymphoid structures located within tumours also provides a possible site where the process of naïve cell priming by DCs is expected (Goc et al., 2013). In addition to the observed cross-presentation of gp100, an alternative melanoma antigen, derived from Melan A, was also cross-presented, resulting in the direct activation of Melan A specific T cells (the occurrence of which has been associated with long-term survival in melanoma patients (Weide et al., 2012)). This type of epitope spreading could lead to the presentation of antigens that may not have been subjected to central tolerance, or that may have previously been down-regulated, thereby increasing the likelihood of inducing an autologous T cell response. Possibly a distinctive feature of ImmTACs in this context is the potential for an enhanced degree of naïve cell priming resulting from the dual engagement of DCs by both ImmTACs and naturally occurring TCRs on the naïve T cell surface. The combined effects of activating both redirected and tumour-specific T cells should serve to counteract tumour-induced immunosuppression and perhaps relieve T cell anergy.” (see page 4, col. bridging paragraph, emphasis added). Fig. 2(D) of Oates mentioned in the paragraph above is reproduced below for reference: PNG media_image1.png 619 1013 media_image1.png Greyscale The idea that a first therapy that kills cancer cells, such as IMCgp100 killing of melanoma cancer cells, can extend the anti-cancer immune response to polyclonal T-cells capable of recognizing a variety of tumor-associated antigens (TAAs) was further echoed by the teachings of Sharma: “The last few decades have witnessed the emergence of two effective but fundamentally different strategies for cancer therapy, each with its own strengths and weaknesses. Genomic-guided identification of mutations that drive cancer has led to the development of drugs that result in remarkable responses in the majority of patients whose tumors have the targeted lesion, but the responses are relatively short-lived. As was the case with chemotherapies, it is not unreasonable that combinations of genomically targeted agents will be more powerful against cancer than single agents. It is possible that the use of multiple agents may enhance their effectiveness in terms of increasing overall survival. However, the myriad of mechanisms of acquired resistance and the complexity of the target landscape due to inherent genomic instability may prove extremely difficult to overcome through the sole use of genomically targeted strategies, attaining to achieve cure. In contrast, immune checkpoint therapy is inherently multivalent because targeting a single checkpoint can potentially release T cells with specificity for peptides derived from many different antigens present in a tumor, including differentiation, cancer testis, and even neoantigens generated by mutational events inherent in the genomic instability that drives cancer (Snyder et al., 2014, Linnemann et al., 2015). As a result of the generation of improved anti-tumor T cell responses, immune checkpoint therapy results in durable responses but only in a fraction of patients. As discussed in the previous sections, it is certainly possible to target multiple immune checkpoints with different mechanisms for improved anti-tumor responses in greater numbers of patients. Will patients benefit from combination of these two strategies?.... From a mechanistic perspective, it is possible that combination strategies with immune checkpoint therapies and genomically targeted agents will result in induction of immune memory, leading to more durable control of tumor growth than what is achievable with either modality alone. Genomically targeted therapies with high objective response rates actually could serve as “cancer vaccines,” inducing the killing of tumor cells and resulting in the release of tumor antigens and neoantigens, which can then be presented by APCs to tumor-specific T cells (Figure 1). These T cells would become activated but also upregulate inhibitory checkpoints such as CTLA-4 and PD-1, which can be blocked with antibodies to permit enhanced anti-tumor T cell responses, including memory T cell responses, to enable long-term control of disease and possible cure. In addition, the use of targeted agents to directly kill tumor cells, with release of tumor antigens, may focus the activated immune response generated by immunotherapy agents on tumor antigens rather than self-antigens expressed on normal tissues, resulting in fewer adverse events. Furthermore, identification of neoantigens may result in the development of personalized vaccines composed of these neoantigens for novel vaccine strategies plus immune checkpoint agents (Gubin et al., 2014, Tran et al., 2014, Linnemann et al., 2015).” (see page 209-10 bridging paragraph – page 211, left col., 1st full paragraph, emphasis added). The above teachings of Sharma were accompanied by Sharma Fig. 1: PNG media_image2.png 998 254 media_image2.png Greyscale PNG media_image3.png 113 338 media_image3.png Greyscale As set forth in the above teachings of Sharma which are graphically displayed in Sharma Fig. 1, immune checkpoint therapy, such as anti-CTLA-4 and anti-PD-1 antibodies, were expected to allow activated, tumor antigen recognizing T-cells to release the “brakes” thereby allowing said T-cells to attack tumor cells. For example, at page 208, right col., last full paragraph, Sharma teaches (emphasis added): “…phase I clinical trials with a monoclonal antibody against PD-1 demonstrated clinical responses in multiple tumor types, including melanoma, renal cell carcinoma, non-small-cell carcinoma (Topalian et al., 2012), Hodgkin’s lymphoma (Ansell et al., 2015), and head and neck cancers (Seiwert et al., 2014, J. Clin. Oncol., abstract). Recently, a large phase I clinical trial with an anti-PD-1 antibody known as MK-3475 showed response rates of ∼37%–38% in patients with advanced melanoma, including patients who had progressive disease after prior ipilimumab treatment (Hamid et al., 2013), triggering the approval of MK-3475 (pembroluzimab, Merck) by the FDA in September 2014. A phase III clinical trial that treated patients with metastatic melanoma with a different anti-PD-1 antibody (nivolumab, Bristol-Myers Squibb, BMS) also demonstrated improved responses and overall survival benefit as compared to chemotherapy treatment (Robert et al., 2015b). Nivolumab was FDA approved for patients with metastatic melanoma in December 2014….” Finally, the idea that APC activated, tumor antigen recognizing T-cells are inhibited from killing tumor cells by their expression of inhibitory receptors such as PD-1 is further echoed in the teachings of Gros. For example, at the final paragraph of their Introduction Gros teaches the following regarding PD-1-expression by tumor antigen recognizing, tumor infiltrating lymphocyte (TIL) in melanoma patients (emphasis added): “We hypothesized that the assessment of unique phenotypic traits expressed by CD8+ TILs and TCR β chain (TCRβ; encoded by TRB) clonotypic immunoprofiling of lymphocytes infiltrating the tumor could provide a powerful platform to study antitumor T cell responses and evaluated their usefulness in identifying the diverse repertoire of tumor-reactive cells. Despite the accepted negative regulatory role of PD-1 in T cells, our findings establish that expression of PD-1 on CD8+ melanoma TILs accurately identifies the repertoire of clonally expanded tumor-reactive, mutation-specific lymphocytes and suggest that cells derived from this population play a critical role in tumor regression after TIL administration.” Further similar to the teachings of Sharma, Gros teaches inhibition of PD-1 on melanoma differentiation antigen recognizing CD8+ T cells to increase their cancer cell killing activity: “Additionally, CD8+ lymphocytes targeting melanoma differentiation antigens in the tumor express PD-1, CTLA-4, TIM-3, and LAG-3 and exhibit impaired IFN-γ and IL-2 secretion (23, 24), supporting a negative regulatory role of PD-1 and inhibitory receptors in naturally occurring T cell responses to cancer and providing a rationale for the treatment of cancer with immune checkpoint inhibitors.” (see page 2254 col. bridging paragraph, emphasis added) When the reference claims are considered in view of the teachings set forth above it would have been obvious to one of ordinary skill in the art wishing to treat advanced melanoma as described by Oates to make use of the method of treatment set forth in reference claim 8 drawn to “[a] method of treating gp100 positive cancer in a patient, comprising: administering to said patient a plurality of doses of a T cell redirecting bispecific therapeutic which comprises (1) a targeting moiety that binds the YLEPGPVTA (SEQ ID NO:1)-HLA-A2 complex fused to (2) a CD3 binding T cell redirection moiety, wherein the bispecific therapeutic includes…, wherein the bispecific therapeutic is administered in combination with one or more anti-cancer therapies,” and in particular to employ the particular combination of, e.g., IMCgp100 (which corresponds to SEQ ID NOs: 4 and 5 of the reference patent) with an anti-PD-1 antibody such as the pembrolizumab antibody, i.e., it would have been obvious to practice instant claims 18 and 20. A reason such a combination would have been very desirable to the ordinarily skilled artisan was because, as taught by Oates, the IMCgp100 T cell redirecting bispecific therapeutic was taught by Bossi et al. 2014 to promote cross-presentation of tumor associated antigens, thereby facilitating “epitope spreading,” a phenomenon widely-recognized to boost the anti-tumor immune response (see the teaching of Sharma above), and as further described by Gros, expression of PD-1 by melanoma infiltrating T-cells would otherwise interfere with TCR signaling triggered by recognition of melanoma expressed antigens, thus the ordinarily skilled artisan would have been motivated to combine administration of the IMCgp100 T cell redirecting bispecific therapeutic with administration of an anti-PD-1 antibody such as the pembrolizumab antibody when treating a gp100 positive cancer such as a gp100 positive melanoma. Moreover, the various steps and elements of instant claims 1, 3, 4, 10-13, 17 and 19 mirror the steps and elements recited in reference claims 1-7 and 8-14, and these claims would be obvious over the reference claims for the same reasons that claims 18 and 20 are obvious over reference claim 8 as set forth above. In view of the reference teachings it was apparent that one of ordinary skill in the art would have had a reasonable expectation of success in arriving at the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Bossi et al. (Cancer Immunol Immunother (2014) 63:437–448). Any inquiry concerning this communication or earlier communications from the examiner should be directed to ZACHARY S SKELDING whose telephone number is (571)272-9033. The examiner can normally be reached M-F 9-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ZACHARY S SKELDING/Primary Examiner, Art Unit 1644
Read full office action

Prosecution Timeline

Oct 19, 2023
Application Filed
Aug 27, 2026
Non-Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780897
TCRS SPECIFIC FOR MINOR HISTOCOMPATIBILITY (H) ANTIGEN HA-1 AND USES THEREOF
3y 2m to grant Granted Nov 03, 2026
Patent 12774345
IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE
4y 1m to grant Granted Oct 27, 2026
Patent 12760119
HETERODIMERIC ANTIBODIES THAT BIND ENPP3 AND CD3
4y 2m to grant Granted Oct 13, 2026
Patent 12747300
Methods and Antibody Compositions for Tumor Treatment
4y 2m to grant Granted Sep 29, 2026
Patent 12742017
ANTI-CD36 ANTIBODIES AND USES THEREOF
2y 0m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
99%
With Interview (+41.3%)
Low
PTA Risk
Based on 836 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month